Your browser doesn't support javascript.
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Corominas, Hèctor; Castellví, Ivan; Diaz-Torné, César; Matas, Laia; de la Rosa, David; Mangues, Maria Antònia; Moya, Patricia; Pomar, Virginia; Benito, Natividad; Moga, Ester; Sosa, Nerea Hernandez-de; Casademont, Jordi; Domingo, Pere.
  • Corominas H; Servei de Reumatologia.
  • Castellví I; Servei de Reumatologia.
  • Diaz-Torné C; Servei de Reumatologia.
  • Matas L; Servei de Medicina Interna.
  • de la Rosa D; Servei de Pneumologia.
  • Mangues MA; Servei de Farmàcia Hospitalària.
  • Moya P; Servei de Reumatologia.
  • Pomar V; Unitat de Malalties Infeccioses.
  • Benito N; Unitat de Malalties Infeccioses.
  • Moga E; Servei Immunologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • Sosa NH; Servei de Medicina Interna.
  • Casademont J; Servei de Medicina Interna.
  • Domingo P; Unitat de Malalties Infeccioses.
Medicine (Baltimore) ; 100(19): e25923, 2021 May 14.
Article in English | MEDLINE | ID: covidwho-1455404
Semantic information from SemMedBD (by NLM)
1. Critical Illness PROCESS_OF Patients
Subject
Critical Illness
Predicate
PROCESS_OF
Object
Patients
2. sarilumab TREATS Critical Illness
Subject
sarilumab
Predicate
TREATS
Object
Critical Illness
3. sarilumab TREATS Cytokine Release Syndrome
Subject
sarilumab
Predicate
TREATS
Object
Cytokine Release Syndrome
4. Cytokine Release Syndrome PROCESS_OF Patients
Subject
Cytokine Release Syndrome
Predicate
PROCESS_OF
Object
Patients
5. sarilumab TREATS Patients
Subject
sarilumab
Predicate
TREATS
Object
Patients
6. sarilumab DISRUPTS interleukin-6 receptor activity
Subject
sarilumab
Predicate
DISRUPTS
Object
interleukin-6 receptor activity
7. sarilumab ASSOCIATED_WITH Disease
Subject
sarilumab
Predicate
ASSOCIATED_WITH
Object
Disease
8. sarilumab AFFECTS Cytokine Release Syndrome
Subject
sarilumab
Predicate
AFFECTS
Object
Cytokine Release Syndrome
9. Critical Illness PROCESS_OF Patients
Subject
Critical Illness
Predicate
PROCESS_OF
Object
Patients
10. sarilumab TREATS Critical Illness
Subject
sarilumab
Predicate
TREATS
Object
Critical Illness
11. sarilumab TREATS Cytokine Release Syndrome
Subject
sarilumab
Predicate
TREATS
Object
Cytokine Release Syndrome
12. Cytokine Release Syndrome PROCESS_OF Patients
Subject
Cytokine Release Syndrome
Predicate
PROCESS_OF
Object
Patients
13. sarilumab TREATS Patients
Subject
sarilumab
Predicate
TREATS
Object
Patients
14. sarilumab DISRUPTS interleukin-6 receptor activity
Subject
sarilumab
Predicate
DISRUPTS
Object
interleukin-6 receptor activity
15. sarilumab ASSOCIATED_WITH Disease
Subject
sarilumab
Predicate
ASSOCIATED_WITH
Object
Disease
16. sarilumab AFFECTS Cytokine Release Syndrome
Subject
sarilumab
Predicate
AFFECTS
Object
Cytokine Release Syndrome
ABSTRACT
ABSTRACT Blocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Interleukin-6 / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Subject: Interleukin-6 / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Type of study: Observational study / Risk factors Language: English Journal: Medicine (Baltimore) Clinical aspect: Therapy Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Interleukin-6 / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Subject: Interleukin-6 / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Type of study: Observational study / Risk factors Language: English Journal: Medicine (Baltimore) Clinical aspect: Therapy Year: 2021
...